[英语研究]慢性乙型肝炎患者的抗病毒药物耐药性测试

StephenW

<http://www.docguide.com/antiviral-drug-resistance-testing-patients-chronic-hepatitis-b?hash=04301bd4&eid=21056&alrhash=2e06a4-d460252966da8019c5213f6ae197892e>

Source: Dig Dis Sci  |  Posted 4 days ago
慢性乙型肝炎患者的抗病毒药物
耐药性测试


Antiviral Drug Resistance Testing in Patients with Chronic Hepatitis B

Wong VW, Wong GL, Tse CH, Yuen LK, Chan HY, Locarnini SA, Chan HL;

Digestive Diseases and Sciences (Jul 2011)

BACKGROUND: Antiviral drugs against hepatitis B virus are limited by the
emergence of drug resistance. AIMS: We aimed to study the impact of drug
resistance testing on treatment decisions. METHODS: In part 1 of this
study, consecutive patients with chronic hepatitis B who had antiviral drug
resistance testing were studied. Part 2 was a two-step questionnaire survey
including ten characteristic case scenarios. Hepatologists were asked about
their treatment decisions before and after the knowledge of drug resistance
results. RESULTS: Fifty-one patients underwent drug resistance testing,
most of whom were on lamivudine, adefovir dipivoxil or entecavir
monotherapy. Thirty-four (67%) patients had drug-resistant mutants
detected, 4 (8%) had low viral load, and 13 (25%) harboured wild-type
virus. Twenty-nine of 34 (85%) patients harbouring drug-resistant mutants
and 9 of 17 (53%) patients with no mutants detected changed their drug
regimens (P = 0.038). In part 2, 18 hepatologists completed all two
questionnaires. Overall, treatment decision was modified in 52% of cases
upon receiving the drug resistance testing results. The detection of
rtA181V/I resulted in decision changes in most hepatologists, with the
preferred treatment switching from tenofovir to entecavir. When no mutants
were detected in partial responders to entecavir monotherapy, most
hepatologists chose to increase the dose of entecavir.
CONCLUSIONS:
Drug-resistant mutations are detected in around two-thirds of chronic
hepatitis B patients undergoing drug resistance testing. Drug resistance
testing alters management in over half of the cases, and should be
considered in all patients with virological breakthrough and suboptimal
virological suppression.

StephenW

谷歌翻译是不是100％准确，仅供参考使用。

来源：挖DIS科学|发表于4天前

慢性乙型肝炎患者的抗病毒药物电阻测试

王大众，黄GL，谢CH，圆劲，陈晔，陈HL，Locarnini SA;

消化系统疾病和科学（2011年7月）

背景：针对B型肝炎病毒的抗病毒药物都是由有限
出现耐药性。目的：我们的目的是研究药物的影响
电阻测试仪的治疗决定。在这第1部分：方法
研究中，患者与慢性乙型肝炎的抗病毒药物
电阻测试进行了研究。第2部分是一个两步的问卷调查
包括10个特点的情况。肝病被询问
他们的治疗决策之前和之后的耐药性知识
的结果。结果：51例进行耐药性检测，
其中大部分是拉米夫定，阿德福韦酯或恩替卡韦
单药治疗。三十四个（67％）患者有抗药性的突变体
检测，4（8％）病毒载量低，13（25％）怀着野生型
病毒。 34二十九个（85％）患者窝藏抗药性突变体
9 17（53％）与没有突变体的患者检测改变了他们的药物
方案（P = 0.038）。在第2部分中，有18个肝病完成所有
问卷调查。总体而言，治疗的决定是在52％的情况下修改
在收到的耐药性检测结果。检测
rtA181V /我决定改变在大多数肝病，与
开关从泰诺福韦恩替卡韦的首选治疗方法。当没有突变体
警方在现场发现部分应答恩替卡韦单药治疗，最
肝病选择增加剂量的恩替卡韦。结论：
耐药突变被发现在大约三分之二的慢性
乙肝患者发生耐药性测试。耐药性
测试改变的情况下，超过半数的管理，并应
考虑在所有患者的病毒学突破和次优
病毒学抑制。